Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients’ Voice or a Missed Opportunity

Juskaran Chadha,Jacob J. Adashek,Heather Jim,Youngchul Kim,Adele Semaan,Nicholas H Chakiryan,Houssein Safa,Ali Hajiran,Wade Sexton,Scott M Gilbert,Brandon J Manley,Philippe E Spiess,Jad Chahoud

Clinical Genitourinary Cancer（2022）

引用 3|浏览12

暂无评分

摘要

•Standardization and reporting of PROs endpoints must be improved.•The time delay between publication of the clinical results and PROs results creates a gap in the knowledge.•Our publication provides clinicians a comparative resource for combination ICB PROs endpoints in mRCC trials.

查看译文

关键词

Health related quality of life,Metastatic renal cell carcinoma,Clear cell carcinoma,Kidney Cancer,Clinical Trial Design

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要